文献速递精神分裂症与精神病性障碍会诊联络精神医学

Primrose干预对重性精神疾病患者胆固醇及心血管风险的效果:整群随机对照试验

Clinical and cost-effectiveness of an intervention for reducing cholesterol and cardiovascular risk for people with severe mental illness in English primary care: a cluster randomised controlled trial.
PubMed 文献 · Lancet Psychiatry · 2018-01-22

BACKGROUND: People with severe mental illnesses, including psychosis, have an increased risk of cardiovascular disease. We aimed to evaluate the effects of a primary care intervention on decreasing total cholesterol concentrations and cardiovascular disease risk in people with se…

核心结论

  • 12个月时Primrose干预与常规治疗组总胆固醇浓度无显著差异。
  • Primrose干预与更低的总医疗费用和精神科住院费用相关,可能具有成本效果。

研究设计与样本

  • 在英格兰全科诊所开展的整群随机对照试验,以全科诊所(每家≥40例重性精神疾病患者)为整群单位,1:1随机分配,区组大小4。
  • 共随机分配76家全科诊所、327例参与者:Primrose组38家诊所155例,常规治疗组38家诊所172例。
  • Primrose干预为初级保健专业人员提供最多12次预约,围绕心血管病预防手册化干预(他汀依从、饮食、体力活动、减少酒精、戒烟);常规治疗仅反馈筛查结果。
  • 主要结局为12个月总胆固醇,主要经济分析结局为医疗费用,采用意向性分析。

主要发现

  • 12个月总胆固醇数据可获取者:Primrose组137例(88%),常规治疗组152例(88%)。

关键数值与推荐

  • 严重不良事件:Primrose组6例住院和1例死亡(共7例),常规治疗组23例(含3例死亡,共18例)。

临床怎么用

  • 在初级保健中为重性精神疾病患者提供结构化心血管风险干预是可行的,但本方案未显著改善12个月总胆固醇。
  • 干预可能降低总医疗费用和精神科住院费用,提示潜在成本效果,需进一步验证。
  • 常规治疗组胆固醇也有下降,提示对照条件较好,评估新干预时应考虑背景照护水平。

局限性

  • 作者指出总胆固醇无差异可能源于整群设计、常规治疗组照护良好、干预持续时间短或对他汀处方的关注不足。
  • 患者和全科诊所工作人员未对分组设盲。
  • 12个月总胆固醇数据在两组均有约12%缺失。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: People with severe mental illnesses, including psychosis, have an increased risk of cardiovascular disease. We aimed to evaluate the effects of a primary care intervention on decreasing total cholesterol concentrations and cardiovascular disease risk in people with severe mental illnesses. METHODS: We did this cluster randomised trial in general practices across England, with general practices as the cluster unit. We randomly assigned general practices (1:1) with 40 or more patients with severe mental illnesses using a computer-generated random sequence with a block size of four. Researchers were masked to allocation, but patients and general practice staff were not. We included participants aged 30-75 years with severe mental illnesses (schizophrenia, bipolar disorder, or psychosis), who had raised cholesterol concentrations (5·0 mmol/L) or a total:HDL cholesterol ratio of 4·0 mmol/L or more and one or more modifiable cardiovascular disease risk factors. Eligible participants were recruited within each practice before randomisation. The Primrose intervention consisted of appointments (≤12) with a trained primary care professional involving manualised interventions for cardiovascular disease prevention (ie, adhering to statins, improving diet or physical activity levels, reducing alcohol, or quitting smoking). Treatment as usual involved feedback of screening results only. The primary outcome was total cholesterol at 12 months and the primary economic analysis outcome was health-care costs. We used intention-to-treat analysis. The trial is registered with Current Controlled Trials, number ISRCTN13762819. FINDINGS: Between Dec 10, 2013, and Sept 30, 2015, we recruited general practices and between May 9, 2014, and Feb 10, 2016, we recruited participants and randomly assigned 76 general practices with 327 participants to the Primrose intervention (n=38 with 155 patients) or treatment as usual (n=38 with 172 patients). Total cholesterol concentration data were available at 12 months for 137 (88%) participants in the Primrose intervention group and 152 (88%) participants in the treatment-as-usual group. The mean total cholesterol concentration did not differ at 12 months between the two groups (5·4 mmol/L [SD 1·1] for Primrose vs 5·5 mmol/L [1·1] for treatment as usual; mean difference estimate 0·03, 95% CI -0·22 to 0·29; p=0·788). This result was unchanged by pre-agreed supportive analyses. Mean cholesterol decreased over 12 months (-0·22 mmol/L [1·1] for Primrose vs -0·36 mmol/L [1·1] for treatment as usual). Total health-care costs (£1286 [SE 178] in the Primrose intervention group vs £2182 [328] in the treatment-as-usual group; mean difference -£895, 95% CI -1631 to -160; p=0·012) and psychiatric inpatient costs (£157 [135] vs £956 [313]; -£799, -1480 to -117; p=0·018) were lower in the Primrose intervention group than the treatment-as-usual group. Six serious adverse events of hospital admission and one death occurred in the Primrose group (n=7) and 23, including three deaths, occurred in the treatment-as-usual group (n=18). INTERPRETATION: Total cholesterol concentration at 12 months did not differ between the Primrose and treatment-as-usual groups, possibly because of the cluster design, good care in the treatment-as-usual group, short duration of the intervention, or suboptimal focus on statin prescribing. The association between the Primrose intervention and fewer psychiatric admissions, with potential cost-effectiveness, might be important. FUNDING: National Institute of Health Research Programme Grants for Applied Research.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Osborn D, Burton A, Hunter R, et al. Clinical and cost-effectiveness of an intervention for reducing cholesterol and cardiovascular risk for people with severe mental illness in English primary care: a cluster randomised controlled trial. Lancet Psychiatry. 2018. PMID: 29396118. doi:10.1016/S2215-0366(18)30007-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。